Gilead files 2nd patent suit against Teva
Gilead Sciences has filed a law suit in the US District Court in New York against Teva Pharmaceuticals USA and its Israel-based parent Teva Pharmaceutical Industries, for infringement of US patent numbers 6,642,245 and 6,703,396. Both patents are associated with emtricitabine, a component of Truvada (emtricitabine and tenofovir disoproxil fumarate) and of Atripla (efavirenz 600mg/emtricitabine 200mg/tenofovir disoproxil fumarate 300mg), and are licensed exclusively to Gilead by Emory University. This is its second suit against Teva.
The law suit follows an Abbreviated New Drug Application filing by Teva, which seeks approval to manufacture and market a generic version of Atripla before the expiration of both emtricitabine patents.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze